National Health (Immunisation Program – Designated Vaccines) Variation Determination (No. 1) 2018 (Cth)

National Health (Immunisation Program – Designated Vaccines) Variation Determination (No. 1) 2018

National Health Act 1953

I, Masha Somi, delegate of the Minister for Health, make this Determination under subsection 9B(2) of the National Health Act 1953.

Dated 16 February 2018

Dr Masha Somi

Assistant Secretary

Immunisation Branch

Office of Health Protection

Chief Medical Officer Group

Department of Health

1. Name of Determination

This Determination is the National Health (Immunisation Program – Designated Vaccines) Variation Determination (No. 1) 2018.

1. Commencement

This Determination commences on the day after registration.

3       Authority

This Determination is made under subsection 9B(2) of the National Health Act 1953.          

1. Variation of National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No. 1)

The Schedule varies the National Health (Immunisation Program – Designated     Vaccines) Determination 2014 (No. 1).

Schedule

[1] Item 101 in Schedule 1, Part 1

Repeal the item, substitute:

101 Vaccine Diphtheria, tetanus and pertussis (adult/adolescent) Circumstances Vaccine may be provided to: (a)     a child who is at least 10 years but less than 18 years old; or (b)   a person who is pregnant. Boostrix Injection (0.5mL) Each of the following: (a)     diphtheria toxoid — not less than 2 IU; (b)     tetanus toxoid — not less than 20 IU; (c)     PT — 8 µg; (d)     FHA — 8 µg; (e)    PRN — 2.5 µg 1 dose (booster)

[2] Item 102 in Schedule 1, Part 1

Repeal the item, substitute:

102 Vaccine Diphtheria, tetanus and pertussis (adult/adolescent) Circumstances Vaccine may be provided to: (a)     a child who is at least 10 years but less than 18 years old; or (b)   a person who is pregnant. Adacel Injection (0.5mL) Each of the following: (a)     diphtheria toxoid — not less than 2 IU; (b)     tetanus toxoid — not less than 20 IU; (c)     PT — 2.5 µg; (d)     FHA — 5 µg; (e)    PRN — 3 µg (f)    FIM 2+3 — 5 µg 1 dose (booster)

[3] Item 103 in Schedule 1, Part 1

Repeal the item, substitute:

103 Vaccine Haemophilus influenza type b (Hib) (monovalent PRP‑T) Circumstances Vaccine may be provided to a child who is about 18 months old. ActHib or Hiberix Refrigerated lyophilised preparation for injection (0.5mL) with separate diluent Purified Hib capsular polysaccharide conjugated to tetanus toxoid — 10 µg 1 dose (booster)

[4] After item 108 in Schedule 1, Part 1

Insert:

108A Vaccine Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate Circumstances Vaccine may be provided to a child who is 12 months old. Nimenrix Injection (0.5mL) After reconstitution, each of the following: (a)     Meningococcal polysaccharide - Serogroup A[1] — 5 μg (b)     Meningococcal polysaccharide - Serogroup C¹ — 5 μg (c)     Meningococcal polysaccharide - Serogroup W-135¹ — 5 μg (d)     Meningococcal polysaccharide - Serogroup Y¹ —  5 μg 1 dose

[1] conjugated to tetanus toxoid carrier protein 44 μg

[5] After item 207C in Schedule 1, Part 2

Insert:

207D Vaccine Influenza Circumstances Vaccine may be provided may be provided to a person who is at least 65 years of age. Fluzone High Dose Injection (0.5mL) 1 dose per calendar year

[6] After item 207D in Schedule 1, Part 2

Insert:

207E Vaccine Influenza Circumstances Vaccine may be provided may be provided to a person who is at least 65 years of age. Fluad Injection (0.5mL) 1 dose per calendar year